Catalio Capital Management, LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Catalio Capital Management, LP disclosed 39 US equity positions worth $532.1m in its Q2 2026 13F filing. The largest position was AVALYN PHARMACEUTICALS INC at 10.4% of the reported book, followed by JNJ and GILD. Against the Q1 2026 filing, it opened 11 new positions, added to 15 and reduced 8 among the top 39 holdings.
What did Catalio Capital Management, LP own in Q2 2026? Top 39 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | AVALYN PHARMACEUTICALS INC | 10.4% | $55.2m | 1,675,830 | – | new | |
| 2 | JNJ JOHNSON & JOHNSON | Healthcare | 6.6% | $35.3m | 138,946 | – | new |
| 3 | GILD GILEAD SCIENCES INC | Healthcare | 6.4% | $34.0m | 269,309 | 64% | added |
| 4 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 6.4% | $33.9m | 455,041 | 5% | added |
| 5 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 5.0% | $26.6m | 1,215,698 | 16% | added |
| 6 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 5.0% | $26.5m | 562,672 | -46% | reduced |
| 7 | BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 4.5% | $23.8m | 412,961 | -2% | reduced |
| 8 | PARABILIS MEDICINES INC | 4.2% | $22.6m | 824,043 | – | new | |
| 9 | NTRA NATERA INC | Healthcare | 4.2% | $22.3m | 82,181 | 16% | added |
| 10 | INCY INCYTE CORP | Healthcare | 4.1% | $21.7m | 191,627 | 5% | added |
| 11 | SEPN SEPTERNA INC | Healthcare | 3.4% | $18.0m | 536,152 | 82% | added |
| 12 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 3.3% | $17.5m | 648,722 | 48% | added |
| 13 | HTFL HEARTFLOW INC | Healthcare | 3.2% | $17.1m | 583,055 | 44% | added |
| 14 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 3.0% | $16.1m | 1,080,888 | 21% | added |
| 15 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 2.8% | $14.8m | 276,550 | 8% | added |
| 16 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 2.5% | $13.1m | 106,799 | – | new |
| 17 | IRON DISC MEDICINE INC | Healthcare | 2.2% | $11.7m | 159,384 | 30% | added |
| 18 | EW EDWARDS LIFESCIENCES CORP | Healthcare | 2.1% | $11.3m | 124,778 | -14% | reduced |
| 19 | AXSM AXSOME THERAPEUTICS INC. | Healthcare | 2.0% | $10.6m | 43,182 | – | new |
| 20 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.0% | $10.6m | 316,252 | -63% | reduced |
| 21 | KAILERA THERAPEUTICS INC | 1.9% | $10.3m | 468,750 | – | new | |
| 22 | KPTI KARYOPHARM THERAPEUTICS INC | 1.7% | $9.2m | 940,855 | 5% | added | |
| 23 | ODYSSEY THERAPEUTICS INC | 1.6% | $8.6m | 457,839 | – | new | |
| 24 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.6% | $8.5m | 31,759 | – | new |
| 25 | KARD KARDIGAN INC | 1.4% | $7.5m | 312,500 | – | new | |
| 26 | ELDN ELEDON PHARMACEUTICALS INC | 1.3% | $6.7m | 1,695,071 | 3% | added | |
| 27 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 1.2% | $6.3m | 471,254 | – | new |
| 28 | MANE VERADERMICS INC | Healthcare | 1.1% | $5.6m | 45,856 | -74% | reduced |
| 29 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.0% | $5.4m | 244,929 | -13% | reduced |
| 30 | GUTS FRACTYL HEALTH INC | 0.9% | $4.9m | 6,168,749 | 12% | added | |
| 31 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.9% | $4.7m | 148,045 | 76% | added |
| 32 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.6% | $3.2m | 32,941 | -94% | reduced |
| 33 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 0.5% | $2.4m | 318,407 | – | new | |
| 34 | TARA PROTARA THERAPEUTICS INC | 0.4% | $2.0m | 520,148 | -10% | reduced | |
| 35 | HYPR HYPERFINE INC | 0.3% | $1.8m | 1,320,041 | 0% | held | |
| 36 | ATAI ATAIBECKLEY INC | 0.2% | $1.0m | 196,858 | 0% | held | |
| 37 | MGX METAGENOMI THERAPEUTICS INC | 0.1% | $629.5k | 528,993 | 0% | held | |
| 38 | OM OUTSET MED INC | 0.1% | $511.0k | 118,279 | 0% | held | |
| 39 | FTH FAETH THERAPEUTICS INC | 0.1% | $367.9k | 14,718 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.